Tricuspid regurgitation (TR) is the most common valvular heart disease, affecting more than 20 million people in the US, including 1.8 million with severe dysfunction.
TR occurs when the tricuspid valve fails to close properly, allowing blood to flow backward from the right ventricle to the right atrium. As severity increases, the heart works harder, leading to reduced quality of life, end-organ dysfunction, and higher mortality.
Bluegrass Pharmaceuticals is a discovery-stage biotech company dedicated to advancing the next generation of Lipid Nanoparticles for superior vaccination efficacy.
While vaccines remain a cornerstone of modern medicine, innovation in protein-based vaccines—which represent over 50% of all vaccines administered—has lagged behind the recent mRNA surge. Current protein-based vaccines rely on aluminum salts (a technology dating back to the 1930s) to boost immune response, yet many still require multiple doses for lasting protection.
About Annoviant
Founded in 2018, Annoviant is a cardiovascular device company developing next-generation regenerative implants that improve durability, reduce complications, and promote natural tissue remodeling.
The company is backed by leading healthcare institutions, research organizations, established vendors, incubator programs, FDA-funded consortia, NIH grants, and private capital.
The Clinical Challenge
The $700 billion natural products market—spanning pharmaceuticals, agriculture/animal health, and consumer health—faces severe production bottlenecks. Many of nature’s most valuable metabolites are produced in trace amounts, blocking clinical trials and cost-effective manufacturing.
Traditional strain improvement is slow and incremental. Even CRISPR delivers only modest gains in genetically intractable microbes.
Inhaled nitric oxide (iNO) is a critical therapeutic gas with vasodilatory, anti-inflammatory, and antimicrobial properties, used to treat life-threatening conditions like pulmonary hypertension.
Current delivery systems are complex, costly, and restricted to major medical centers. They rely on highly diluted NO in nitrogen, require specialized scrubbers for toxic NO₂, frequent consumable changes, and large, non-portable equipment—limiting broader adoption and increasing care complexity.
Vocalis Care is a healthcare communication company dedicated to eliminating language barriers at the bedside.
Our core product is a mobile app that enables real-time, context-aware communication between clinicians and patients who do not share a language. Designed specifically for hospital and clinic use on hospital-issued devices, it ensures medically relevant and culturally appropriate interactions when clarity is most critical.
SelSym Biotech is a preclinical-stage company focused on improving survivability after severe hemorrhage—the leading cause of death in populations under 45, both domestically and globally.
Most trauma-related deaths occur early due to ineffective bleeding interventions. Current options are limited:
EndoLimb Orthoplastic Solutions, Inc. is advancing the EndoThumb, a transformative implantable device designed to address the significant unmet need in thumb amputation reconstruction.
Thumb amputation causes profound disability—the thumb accounts for:
Atomistic Insights is an AI-driven drug discovery platform that makes previously intractable targets druggable by addressing a core limitation in small-molecule discovery: reliance on static protein structures.
30 million Americans suffer from food allergies, with 6 million affected by peanut allergy—a life-threatening condition with no robust, disease-modifying treatments widely adopted.
Current management relies on strict avoidance and emergency epinephrine, leaving patients and families in constant fear of accidental exposure.
